Patent details

LUC00043 Product Name: Rolapitant, optionally in the form of a pharmaceutically acceptable salt, including rolapitant hydrochloride monohydrate

Basic Information

Publication number:
LUC00043
Type:
SPC
SPC Type:
Medical
Basic Patent Number:
EP028051670
Legal Status:
Invalid
Application number:
LUC00043
First applicant's nationality:
Procedural language:
French

Marketing Authorization

Marketing Authorization Number:
EU/1/17/1180/001
Marketing Authorization Type:
Marketing Authorization Date:
24/04/2017
Marketing Authorization Status:
Accepted
Marketing Authorization Country:
Luxembourg (LU)

Dates

Filing date:
11/10/2017
First Marketing Authorization date:
24/04/2017
Grant date:
20/12/2017
Activation date:
Publication date:
16/10/2017
Lapsed date:
Expiration date:
Renunciation date:
Revocation date:
Annulment date:
Basic SPC Expiration:
17/12/2027
SPC Extension Expiration:
17/12/2027
Rejection date:
Withdrawal date:

Owner

From:
11/10/2017
 
 

Name:
Tesaro, Inc.
Address:
1000 Winter St. North, Waltham, Massachusetts 02451, United States (US)

Agent

Name:
DENNEMEYER & ASSOCIATES S.A. PATENT DEPARTMENT
From:
11/10/2017
Address:
PO Box 1502, 1015, LUXEMBOURG, Luxembourg (LU)
To:

Publication

Bulletin

1

Bulletin Heading:
SPC1
Bulletin edition number:
2017/07
Publication date:
11/12/2017
Description:
Section C : Published requests for Supplementary Protection Certificates – I1 publication

2

Bulletin Heading:
SPC2
Bulletin edition number:
2018/02
Publication date:
15/01/2018
Description:
Section D : Granted supplementary protection certificates – I2 publication

Annual Fees

Annual Fee Due Date:
02/01/2023
Annual Fee Number:
21
Annual Fee Amount:
410 Euro
Expected Payer:
Last Annual Fee Payment Date:
Last Annual Fee Paid Number:
Payer:
Filing date Document type Number of pages
11/10/2017 General Document 3
16/10/2017 Publication 1
11/10/2017 General Document 30
11/10/2017 General Document 1
20/12/2017 Certificate 1
20/12/2017 Publication 1
16/10/2017 Outgoing Correspondence 1
11/10/2017 Application Form 5
11/10/2017 General Document 5